The Microbiome in Cancer Immunotherapy

Aadra Bhatt, Ph.D., Post-Doctoral Fellow, Chemistry, University of North Carolina at Chapel Hill

I am currently a postdoctoral fellow in Dr. Matthew Redinbo's lab in the Department of Chemistry. I'm using novel pharmacological agents to modulate gastrointestinal microbiota.

Shrish Budree, M.D., Senior Clinical Research Fellow, Clinical Research, Openbiome

Dr. Budree is a pediatrician and pediatric gastroenterologist who trained in South Africa and is currently pursuing his PhD. His research is focused on the role of the intestinal microbiome in childhood disease. He completed his medical, pediatric and pediatric gastroenterology training at the University of Cape Town and the Red Cross Children’s Hospital in South Africa. He worked as a research fellow for a year on a large Gates Foundation funded pediatric cohort study based in Cape Town, South Africa. He then completed a microbiome fellowship in the Xavier microbiome laboratory at Massachusetts General Hospital and the Broad Institute of Harvard and MIT in Boston, in which he focused on 16S rRNA and metagenomic sequencing and analysis of the intestinal microbiome. Dr. Budree then joined OpenBiome as their senior clinical research scientist in July 2016. He is currently involved in numerous fecal microbiome transplantation (FMT) trials both in the U.S. and globally. His interest in fecal microbiome transplantation stems from both his clinical gastroenterology background and his current microbiome research.

Rodolphe Clerval, Chief Business Officer, Vice President US Operations, Enterome Bioscience

Before joining Enterome, Rodolphe Clerval was VP Corporate and Business Development of TcLand Expression, a molecular diagnostic company. During his tenure with TcLand Expression, he led strategic planning activities and closed several collaborations and licensing deals. Previously he was Business Development Manager at Genzyme. Prior to this he was financial analyst for the brokerage firm Natixis Bleichroeder. Earlier in his career, Rodolphe served as Research Scientist at Aventis Animal Nutrition.

Julia Drewes, Ph.D., Post-Doctoral Fellow, Oncology, Johns Hopkins School of Medicine, Bloomberg Kimmel Institute for Immunotherapy

Julia has studied the interactions between various microbes and the immune response for over 10 years. After studying the role of hepatitis C virus in liver cancer as an undergraduate at Stanford University in the laboratory of Dr. Peter Sarnow, Julia went on to pursue a PhD at Johns Hopkins with Dr. Christine Zink, focusing on the immunosuppressive pathways regulated by IDO and PD1/PDL1 during HIV and SIV infection. Finding a wide range of parallels between these mechanisms in HIV and the immunosuppressive tumor microenvironment during cancer, in 2014 Julia joined the laboratory of Cynthia Sears for her postdoc, with co-mentorship from Drew Pardoll, at the Bloomberg-Kimmel Institute for Immunotherapy at Johns Hopkins. Julia's current projects include work on bacterial biofilm-mediated carcinogenesis in colorectal cancer as well as fecal microbiota transplant therapy for pediatric patients with recurrent C. difficile.

Vancheswaran Gopalakrishnan, Ph.D., Post-Doctoral Fellow, Surgical Oncology, University of Texas MD Anderson Cancer Center

Dr. Gopalakrishnan is a translational scientist who is committed to advancing the treatment of cancer through iterative studies in mouse and man. He is a trained dentist who obtained his degree from Bapuji Dental College and Hospital, India in 2010. He also has a PhD in cancer epidemiology, during which time he joined the laboratory of Dr. Jennifer Wargo at the University of Texas MD Anderson Cancer Center to lead studies in characterizing the human microbiome. Dr. Gopalakrishnan’s work focuses on better understanding differential responses to cancer therapy through analysis of the oral and gut microbiomes with parallel studies in matched tumor and blood samples as well as in murine models. In a cohort of anti-PD-1 treated melanoma patients, he has helped identify differential signatures in the diversity and composition of the gut microbiome in patients who respond compared to those who do not. Dr. Gopalakrishnan has been incredibly productive, and has presented his work at several international meetings. His goal is to become a leader in translational research.

Lata Jayaraman, Ph.D., Head, Tumor Immunotherapy, Seres Therapeutics

No biography available

Manuel Maia, M.D., Fellow, Medical Oncology, City of Hope

Dr Maia finished his medical oncology fellowship at Instituto do Câncer do Estado de São Paulo (ICESP-Brazil) in 2016. After finishing his training, he moved to California to start a research fellowship in genitourinary medical oncology under the mentorship of Dr Sumanta Pal. Ever since he joined Dr. Pal’s team, he has been conducting prospective studies involving biomarkers in kidney cancer, especially related to circulating tumor DNA and the relationship of gut microbiome and response to immunotherapies.

His areas of research and expertise involve biomarkers and immunotherapies in GU malignancies (kidney, prostate and bladder cancer).

Arpita Maiti, Ph.D., Senior Director, External Science & Innovation, Inflammation & Immunology, Microbiome, Pfizer, Inc.

As Senior Director, External Science & Innovation (ES&I), Arpita is a member of the external opportunities (discovery to Proof of Concept) search and evaluation team for Inflammation & Immunology, at Pfizer. She also leads strategy and partnering efforts in the microbiome for Pfizer. ES&I is an externally-focused scientific team of PhDs / MDs, embedded within Pfizer research groups, that identifies late-breaking science forming the basis of innovative therapies, and drives related collaborations that deliver value to Pfizer, its partners, and patients. Prior to Pfizer, she was Associate Director of R&D Alliance Design & Management at Vertex Pharmaceuticals. Arpita got her start in biotech at Angiotech Pharmaceuticals, heading the Cell Biology & Drug Screening group. She trained as an immunologist and has a PhD and MSc in Immunology from UBC and a BSc from Trinity College, UofT. In addition to presenting at pharma innovation and microbiome conferences, she co-organized the 12th World Congress on Inflammation held in 2015, and has served on the board of the Inflammation Research Association in numerous positions, including as its President (2012-14).

Pranab Mukherjee, MSc, Ph.D., Associate Professor, Dermatology, Case Western Reserve University

My major research interest is to investigate the role of microbiome in human health and disease, and leverage the knowledge gained from such analyses to identify probiotic and biochemical targets that can be developed as targeted therapies. In support of my research goals, I have characterized the bacterial microbiome (bacteriome) as well as fungal microbiome (mycobiome) concomitantly in health and in several disease conditions including atopic dermatitis, Crohn’s disease, and HIV infection. I was instrumental in developing the field of fungal microbiome, and our group coined the term "mycobiome" to describe the fungal microbial community. I have also conducted studies exploring the interactions of microbiome with the host immune system, in collaboration with leading scientists. In more directly translational applications, I have characterized the bacterial and fungal microbiome on affected and unaffected skin of atopic dermatitis patients, and identified intra- and inter-kingdom interactions among the microbes that are specific to affected skin. In addition, I also identified several key interactions between the microbiota and host skin immune response that may be critical to the sustained inflammatory response observed in atopic dermatitis patients. I have also expanded my investigation to include a second inflammatory skin condition, psoriasis, a common skin disease affecting >5M individuals in the U.S. I have attracted funding from industrial partners to support my skin microbiome research. I co-authored a recent Nature Reviews article, outlining the role of mycobiome in disease and published detailed methodology for microbiome sequencing (Methods Mol. Biol.). In addition, I have conducted microbiome/bacteriome and mycobiome analyses of oral samples collected from patients with oral cancer, HIV infection (smokers and non-smokers), as well as from Intensive Care Unit patients. Using correlation analyses I identified microbe-microbe interactions that modulate changes in the microbiome of both skin and gut diseases. As a key component of my microbiome research efforts, I have established a robust bioinformatics and statistical analysis with hands-on experience in statistical programming languages and software workflow (R, SAS, SPSS). I have extensive experience in microbial biofilms, across the areas of microarray analyses, proteomics, lipidomics, targeted mutations, antifungal susceptibility, mechanisms of resistance, developing in vitro models (denture, catheter, contact lenses) as well as animal models (mice, rabbit). I have continued to leverage my experience in microbial biofilms to evaluate the functional clinical relevance of the microbiome, more recently in the setting of skin diseases such as atopic dermatitis and psoriasis, as well as HIV infection. I have also translated my research findings into clinical and translational applications. A recent example of this can be seen in my clinical research focused on the identification of gentian violet as an alternative therapy for oral candidiasis in HIV-infected patients (Mukherjee et al. AIDS. 2017 Jan 2; 31(1):81-88). Separately, as part of a collaboration with Dr. Robert Salata, we conducted a randomized, double-blinded, placebo-controlled pilot clinical trial to evaluate the safety and efficacy of on oral antiviral formulation in the prevention of upper respiratory infections, and presented the results in BMC Infectious Diseases (Mukherjee et al. BMC Infect. Dis. 2017 Jan 14;17(1):74). Over the years, my research has been supported by funding from federal (NIH) and non-federal funding agencies (Dermatology Foundation, National Eczema Association, National Psoriasis Foundation, Steris Foundation).

Julia Oh, Ph.D., Assistant Professor, The Jackson Laboratory for Genomic Medicine

Dr. Julia Oh is an Assistant Professor at the Jackson Laboratory for Genome Medicine and a microbiome expert. Her current research focuses on technologies to explore and engineer the human microbiome, the communities of bacteria, viruses, and fungi that inhabit all areas of the human body and play an integral role in human health. She has significant training in genomics, genetics, and technology development, completing postdoctoral training at the National Human Genome Research Institute, her Ph.D. in genetics at Stanford University under renowned geneticist and technologist Ronald Davis, and her B.A. from Harvard University at the FAS Center for Systems Biology.

Sandip Patel, M.D., Assistant Professor, Cancer Immunotherapy Program, Experimental Therapeutics, Thoracic Oncology; Assistant Director, Clinical Trials Office, Medicine/Hematology & Oncology, University of California, San Diego Moores Cancer Center

Sandip Patel, MD, is a board-certified medical oncologist who specializes in cancer immunotherapy and early phase clinical trials involving immunotherapy across all types of cancer. Dr. Patel is focused on developing personalized therapies that stimulate a patient’s immune system to attack their specific tumor. He believes in offering these promising immunotherapeutics across all tumor types.

As an assistant professor in the Department of Medicine, Dr. Patel instructs medical students, residents and fellows. His research focuses on developing biomarkers for personalized immunotherapy to better determine which combination of therapies works best for each individual.

Dr. Patel completed a fellowship in medical oncology and hematology at Duke University School of Medicine, Duke Medical Center, and a residency in internal medicine at UC Los Angeles School of Medicine, UCLA Medical Center. He earned his medical degree at Baylor College of Medicine, while performing research at MD Anderson Cancer Center. He is board-certified in internal medicine, medical oncology, and hematology.

William Smith, Principal Research Associate, Research, Vedanta Biosciences, Inc.

William Smith graduated with a bachelor of science in chemistry from the University of North Carolina at Chapel Hill in 2004. His research focus has been in the areas of cell biology and assay development. His work Qualyst Transporter Solutions supported the development and commercialization of a novel primary hepatocyte model for hepatic drug transport and drug-drug interactions. After leaving Qualyst as the Director of Business Operations in 2014, Will shifted focus to bridge the gap between traditional sales and operational science as a Client Manager for Charles River Laboratories (CRL). There he supported academic, government and industrial clients through the design and implementation of preclinical oncology studies at CRL. Through this work, he developed an expertise in the growing immune-oncology field and has leveraged this experience to lead the design and implementation of a preclinical strategy to develop an interventional microbiome therapeutic product to increase the efficacy of immune checkpoint inhibitors.

Anita Y Voigt, Ph.D., Post-Doctoral Researcher, The Jackson Laboratory for Genomic Medicine

Anita, a joint postdoctoral fellow with the Oh and Weinstock groups, is most recently from Heidelberg, Germany, where she studied with Dr. Peer Bork and Dr. Magnus von Knebel Doeberitz on numerous microbiome projects related to colorectal cancer and methods development. She is interested in understanding the fundamental roles of the microbiome, particularly the skin and the gut microbiome, in health and disease.

Targeting Innate Immune Cells

Sungyoo Cho, Ph.D., CSO, Green Cross LabCell

No biography available

Mark Exley, Ph.D., Vice President, Agenus

Dr. Exley got his Ph.D. from London University and postdoc at the Dana-Farber Cancer Institute, Harvard Medical School (HMS). He worked in industry on stimulating and tolerizing vaccines before returning to HMS as Faculty. Mark functionally defined human ‘NKT’ cells as well as ascribed roles to murine NKT. He became Professor at Manchester University, UK before returning to the U.S. as VP, Cellular Immunology, Agenus, Inc. Mark continues to focus on regulation of immunity and how this knowledge can be exploited clinically in cancer (where an NKT trial was recently published), and other diseases.

Kelsey Gauthier, Ph.D., Scientist, Aduro BioTech

Kelsey E. Sivick Gauthier was a postdoc in the Greg Barton lab, part of the Division of Immunology and Pathogenesis in the Department of Molecular and Cell Biology at the University of California, Berkeley, from 2010-2014. She is now a scientist at Aduro Biotech.

Jeremy R. Graff, Ph.D., CSO and Senior Vice President, Research, Biothera Pharmaceuticals, Inc.

Dr. Jeremy Graff completed his Ph.D. thesis on ras oncogene signaling in 1994 at the University of Kentucky. He then proceeded to do postdoctoral research in the laboratory of Dr. Stephen B. Baylin at Johns Hopkins University on the epigenetic silencing of metastasis suppressor genes. From Johns Hopkins, he was recruited to Eli Lilly and Company in 1998 to join the Prostate Cancer Group. At Lilly, Dr. Graff was responsible for delivering new targets and new molecular entities to the clinic for cancer therapy. Dr. Graff’s lab focused on signaling through the AKT/mTOR/ eIF4E pathway and delivered the first eIF4E specific inhibitor to the clinical in collaboration with Dr. Eric Marcusson at Isis Pharmaceuticals. Dr. Graff’s lab was also responsible for the scientific development of enzastaurin- a small molecule inhibitor of AGC kinases. Working in close collaboration with clinical development, Dr. Graff recognized the critical need for enduring pre-clinical science in enabling successful clinical development and patient selection strategies. He championed the development of a defined Translational Oncology effort at Lilly and was afforded the opportunity to build and lead this unprecedented group from 2009-2014. In late 2014, he was recruited to a privately held biotech- Biothera, Inc. to lead the research and enable the clinical success of Imprime PGG- a yeast beta-glucan that acts therapeutically to enlist the functionality of the innate immune system in mounting a coordinated anti-cancer immune attack in concert with therapeutic monoclonal antibodies, anti-angiogenics and checkpoint inhibitors. Dr. Graff was the recipient of the Lilly Research Lab’s most prestigious annual award, the LRL President’s Award. He has published more than 60 peer-reviewed research articles that have garnered more than 14,000 citations in the scientific literature. He currently serves on the editorial board for the journal Cancer Research and has participated as a grant review panelist for more than a decade for the American Cancer Society, the Department of Defense, the NIH/NIDDK, and Genome Quebec.

Alex Karlsson-Parra, M.D., Ph.D., CSO, Immunicum

Alex Karlsson-Parra, M.D., Ph.D. is the Founder of Immunicum AB and serves as its Chief Scientific Officer. As Adjunct Professor in Clinical Immunology, Uppsala University, Sweden, Dr. Karlsson-Parra has over 20 years of experience working in the field of transplantation immunology and is former chairman of the Swedish Expert Group for Clinical Immunology. He was awarded the Athena Prize, the Swedish healthcare’s most prestigious award for clinical research, in 2014. He was formerly Associate Professor and chief physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg.

Dan Kaufman, M.D., Ph.D., Professor, Director of Cell Therapy Program, University of California, San Diego

Dan Kaufman, M.D., Ph.D., is a board-certified hematologist who specializes in caring for patients with blood cancers such as leukemia, lymphoma and myeloma. He is one of the physicians with the joint UC San Diego Health / Sharp Blood and Marrow Transplantation (BMT) Program, which provides patients with the unique opportunity to receive care from the same physician throughout all phases of blood cancer treatment. This includes initial consultation and diagnosis, treatment to help achieve remission, care during stem cell transplant procedures, and follow-up survivorship care. Dr. Kaufman’s expertise and areas of interest include cell-based immunotherapies, stem cells, regenerative medicine and natural killer (NK) cell-mediated therapy. Dr. Kaufman is a faculty member in the Division of Regenerative Medicine at UC San Diego School of Medicine, with the goal of bringing new therapies to clinical trials for diseases caused by injury, age, or degeneration where there is currently no suitable treatment or cure. He directs the cell therapy program, which brings together university and community investigators and national and international collaborators to advance clinical trials of new cell-based therapies. He also leads a research lab that uses human pluripotent stem cells to understand blood cells and related mesodermal cell populations. Using human pluripotent stem cells, Dr. Kaufman and his colleagues aim to develop new clinical applications for treating relapsed or refractory cancers, including both hematologic malignancies and solid tumors. Additionally, as a professor in the Department of Medicine, Dr. Kaufman instructs medical students, residents and fellows at UC San Diego School of Medicine. Dr. Kaufman has co-authored many peer-reviewed articles and his work has appeared in Blood, Journal of Clinical Oncology and Biology of Blood and Marrow Transplantation, among others. He serves on the editorial board and as a reviewer for numerous medical journals. He also speaks frequently at national and international conferences on topics such as stem cell biology, regenerative medicine, immunotherapy and blood cell development. Prior to joining UC San Diego Health, Dr. Kaufman served on faculty at University of Minnesota Medical School for 13 years, where he was recently a professor in the Department of Medicine and associate director of the Minnesota Stem Cell Institute. Dr. Kaufman completed a fellowship in hematology and a residency in internal medicine at University of Wisconsin-Madison, University of Wisconsin Hospital and Clinics. He earned his medical degree from Mayo Medical School and obtained a PhD in immunology at Mayo Graduate School in Rochester, Minnesota. Dr. Kaufman is board-certified in hematology. He is a member of many professional organizations, including the American Society of Hematology, the American Society for Blood and Marrow Transplantation, and the International Society for Stem Cell Research.

Hans Klingemann, M.D., Ph.D., Vice President, Research & Development, NantKwest, Inc.

Dr. Klingemann is the inventor of the NK-92 cell line and co-founded ZelleRx Corp. in 2002, which became Nantkwest in 2015. Dr. Klingemann received his M.D. from the University of Würzburg Medical School, and his Ph.D. from the University of Marburg, Germany. He received specialty training in Stem Cell Transplantation under Nobel Laureate Dr. ED. Thomas at the Fred Hutchinson Cancer Research Center in Seattle. Before founding ZelleRx (which later was renamed ConKwest), Dr. Klingemann was the Director of the Bone Marrow and Stem Cell Transplant Program and the Director for Hematological Malignancies at Tufts Medical Center in Boston. Dr. Klingemann also served as Director of the Section of Bone Marrow Transplant & Cell Therapy at Rush University Medical Center in Chicago where he established the first clinical GMP Cell Therapy facility in the Chicago area. Over the past 25 years, Dr. Klingemann has conducted National Cancer Institute supported research on how to engineer the patient’s immune system to fight cancer, resulting in over 200 peer-reviewed publications. He is author and editor of several books on stem cell transplantation. Dr. Klingemann has been selected as Boston’s Top Doctor for the several years and was named by US News and World Report as one of the leading oncologists in the country. He maintains an academic appointment at Tufts University Medical School.

Tania Konry, Ph.D., Assistant Professor, Department of Pharmaceutical Sciences, Northeastern University

Dr. Konry’s bioengineering background has led her to view science primarily as a problem-solving initiative. Dr. Konry’s laboratory at Northeastern University is focused on developing novel Bio-MEMS approaches to advance point of care diagnostics, cell culture and drug screening and delivery methods. She has developed Lab-on-a-Chip (LOC) devices that integrate several laboratory functions such as real time monitoring of target clinically relevant analyte, proteomics, genomics, cell-cell interactions as well as cell secretion and surface monitoring of single cells on a microchip. In the Single Cell field, the LOC devices developed by her group permit controlled compartmentalization of cell pairs and secreted products within sub-nanoliter volumes and thereby controls cell-to-cell communication by limiting it to interactions between the co-encapsulated cells. It allows monitoring of both contact-dependent (immune synapse formation, delivery of lytic hits) and contact-independent cellular interactions (release of cytokines, chemokines) simultaneously. This dynamic single-cell experimental model provides preclinical information particularly relevant to the scenario of immune cell-cancer cell interactions. Her single-cell project was awarded with R21/NIH/NCI. Dr. Konry was nominated as Phase 1 Finalist of Follow That Cell Challenge/NIH and spotlighted in GEN magazine on her work in single-cell work. She also was recognized with Schumacher Faculty Award, presented to one faculty member early in their Northeastern career for significant academic achievement at Northeastern University and received a competitive BD Biosciences immunology research award for analyzing immune-tumor cell interactions in dynamics with single-cell resolution. Her collaborative effort was also selected for funding by Dana-Farber Cancer Institute/Northeastern University Joint Program in Cancer Drug Development.

Jane Lebkowski, Ph.D., President, R&D and CSO, Asterias

Jane Lebkowski has been actively involved in the development of cell and gene therapies since 1986 and is currently Chief Scientific Officer and President of R&D at Asterias Biotherapeutics, Inc., where she is responsible for all preclinical product development of Asterias’ products. From 1998 to 2012, Dr. Lebkowski was Senior Vice President of Regenerative Medicine and Chief Scientific Officer at Geron Corporation. Dr. Lebkowski led Geron’s human embryonic stem cell program, being responsible for all research, preclinical development, product development, manufacturing, and clinical development activities. Prior to Geron, Dr. Lebkowski was Vice President of Research and Development at Applied Immune Sciences. Following the acquisition of Applied Immune Sciences by Rhone Poulenc Rorer (RPR, currently Sanofi), Dr. Lebkowski remained at RPR as Vice President of Discovery Research. Dr. Lebkowski received her Ph.D. in Biochemistry from Princeton University in 1982, and completed a postdoctoral fellowship at the Department of Genetics, Stanford University in 1986. Dr. Lebkowski has published over 70 peer reviewed papers and has 13 issued U.S. patents. Dr. Lebkowski currently serves on the board of directors of the American Society of Gene and Cell Therapy and serves on several scientific advisory boards and other professional committees.

Holger Lode, Ph.D., Professor and Chair of Pediatrics, Pediatric Hematology and Oncology, University Medicine Greifswald

No biography available

Bahram (Bob) Valamehr, Ph.D., MBA, Vice President, Cancer Immunotherapy, Fate Therapeutics, Inc.

Bahram (Bob) Valamehr is the Vice President of Cancer Immunotherapy at Fate Therapeutics, overseeing the company’s immuno-oncology and pluripotent stem cell programs, including efforts to develop novel pluripotent cell strategies to create “off-the-shelf” cell-based cancer immunotherapeutics. Previously, Dr. Valamehr has played key scientific roles at Amgen and at the Broad Stem Cell Research Center developing ways to modulate stem cell fate and better understand cellular signaling pathways associated with cancer. He has co-authored studies related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA and his MBA from Pepperdine University.

Bin Zheng, Ph.D., Assistant Professor, Dermatology, Harvard Medical School, Massachusetts General Hospital

Dr. Zheng earned his Ph.D. in Molecular Pathology from University of California, San Diego in 2002. His postdoctoral training took place at UCSD in Cell Biology, 2003, and Beth Israel Deaconess Medical Center, Harvard Medical School on Signal Transduction / Cancer Biology in 2008. Honors include: 1997-2000 Huang Memorial Scholarship, University of California, San Diego; 2002-2003 Postdoctoral Fellowship, American Heart Association; 2005-2007 Charles King Trust Postdoctoral Fellowship; 2008 AACR Scholar-in-training Award; 2008-2013 The Pathway to Independence Award (K99/R00), NIH/NCI; 2010 Keystone Symposia Scholarship; 2011-2014 Elizabeth and Oliver Stanton - MRA (Melanoma Research Alliance) Young Investigator Award; 2011 Alexander and Margaret Stewart Trust Pilot Project Award; 2011 V Scholar, The V Foundation for Cancer Research; 2013 Irma T. Hirschl Trust Career Scientist Award. The focus of his laboratory research at Massachusetts General Hospital / Harvard Medical School is metabolic signaling in melanoma, with an interest in understanding how rewired metabolism in cancer cells is coordinated with other hallmarks of cancer to influence caner initiation, promotion and progression.

Neoantigen Based Personalized Immunotherapies

Philip M Arlen, President & CEO, Precision Biologics

Dr. Arlen is the President, CEO and Chief Medical Officer of Precision Biologics. Prior to this he served as President, CEO, and Chief Medical Officer at Neogenix Oncology, Inc. Dr. Arlen spent 11 years at the National Cancer Institute, USA, most recently as the Director of the Clinical Research Group for the Laboratory of Tumor Immunology and Oncology. At the NCI, Dr. Arlen focused on the development of a programmatic approach to vaccine clinical trials conducted at the NCI as well as at numerous other Cancer Centers throughout the U.S. During his tenure at the NCI, Dr. Arlen was the Principal Investigator and/or Associate Investigator on numerous clinical trials involving the use of cancer vaccines and other immunostimulatory molecules. Dr. Arlen remains on the clinical staff at both the NCI Clinical Center as well as the Walter Reed National Military Medical Center. He has authored or co-authored over 100 peer reviewed manuscripts in internationally known scientific and medical journals. Dr. Arlen received an NIH Award of Merit for major contributions to the field of cancer immunotherapy in 2003. He is a board certified medical oncologist and received his BA from Emory University and his MD from Medical College of Georgia, School of Medicine.

Ezra Cohen, M.D., Associate Director, Moores Cancer Center, Professor of Medicine, University of California San Diego

Ezra Cohen, MD, an internationally renowned translational researcher, has been acknowledged for his contribution to the National Cancer Institute Task Force on PI3 Kinase/AKT/mTOR Targeting. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted therapy. His recent National Institutes of Health-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of mechanisms to overcome resistance. He was recently appointed as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease.Dr. Cohen is Associate Director, Translational Science and team leader in Head and Neck Oncology as well as the Solid Tumor Therapeutics research program at Moores Cancer Center at UC San Diego Health. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he chairs the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, C3 steering committee, and the cancer center’s Executive Committee.Dr. Cohen is editor-in-chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and has chaired the most recent two Multidisciplinary Head and Neck Cancer Symposia—the largest international meeting of its kind—sponsored by the American Society for Radiation Oncology, the American Society of Clinical Oncology and the American Head and Neck Society. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr. Cohen has authored more than 120 papers and has presented his research at national and international meetings. In addition, he is Chair of the Career Development Subcommittee of the American Society of Clinical Oncology and has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research. Dr. Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr. Cohen was Co-Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr. Cohen also mentored and developed young faculty in his program.

Agnete Fredriksen, Ph.D., CSO, Vaccibody

Agnete B. Fredriksen joined Vaccibody as Chief Scientific Officer in 2007. She holds a M.Sc., Ph.D. from Institute of Immunology, University of Oslo, Rikshospitalet Medical Center, Oslo where she designed and developed the first Vaccibodies. Previous employments include Researcher at Affitech AS, Oslo and Medinnova AS. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies.

Matthew M Gubin, Ph.D., Instructor, Schreiber Lab, Pathology and Immunology, Washington University School of Medicine

Matthew M. Gubin, PhD is an Instructor in lab of Robert D. Schreiber, PhD in the Department of Pathology and Immunology and in the Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs) at Washington University School of Medicine. His research interests include cancer immunology and immunotherapy. More specifically, his work has focused on immunogenomic approaches to uncover the antigenic targets of T cells during cancer immunotherapies such as checkpoint blockade therapy. Dr. Gubin demonstrated in preclinical models that tumor-specific mutant antigens can be rapidly identified and used as effective personalized neoantigen cancer vaccines when given either alone or in combination with other immunotherapies. Dr. Gubin continues to focus on improving personalized neoantigen vaccines and to examine how antigen immunodominance may influence anti-tumor T cell responses. Dr. Gubin has received a Cancer Research Institute Fellowship to pursue this research. Dr. Gubin received his BS degree in Biology and PhD in Immunology from the University of Missouri in 2004 and 2012 respectively.

James R. Heath, Professor of Physics, Chemistry, California Institute of Technology

James R. Heath is the Elizabeth W. Gilloon Professor and Professor of Chemistry at Caltech, and Professor of Molecular & Medical Pharmacology at UCLA, and Director of the National Cancer Institutes NSB Cancer Center. Heath received a B.Sc. degree in 1984 (Baylor) and his Ph.D. in Chemistry (Rice) in 1988 where he was the principal student involved in the Nobel Prize–winning discovery of C60 and the fullerenes. Heath was a Miller Fellow at UC Berkeley from 1988-91, and on the Technical Staff at IBM Watson Labs from 1991-93. In 1994 he joined the faculty at UCLA. He founded the California NanoSystems Institute in 2000 and served as its Director until moving to Caltech. Heath’s lab works on fundamental problems at the interface of the chemical, physical, biological and biomedical sciences, with focus areas of molecular biotechnologies, and oncology. The biological/biomedical research is relatively new (past 10 years) as Heath’s previous research history was in the areas of nanomaterials, solid-state physics, and nano/molecular electronics.He has received a number of awards, including a Public Service Commendation from Governor Grey Davis, the Sackler Prize, the Spiers Medal, the Feynman Prize, the Jules Springer Prize, and the Arthur K. Doolittle Award. He has founded or co-founded several companies, including NanoSys, MTI, MoB, and Homestead Clinical Corporation, and he serves on the board of a number of organizations, including the Board of Scientific Advisors of the National Cancer Institute.

Suchit Jhunjhunwala, Ph.D., Scientist, Bioinformatics & Computational Biology, Genentech

Karin Joos, Ph.D., CSO, Gritstone Oncology

Dr. Karin Jooss serves as executive vice president of research and chief scientific officer. She joined Gritstone from Pfizer, where she was head of cancer immuno-therapeutics in the Vaccine Immuno-therapeutics Department. While at Pfizer, she built and led immuno-oncology teams, was a member of the vaccine immuno-therapeutics leadership team, and served as head of the immuno-pharmacology team. Her responsibilities included overseeing the assessment of all cancer vaccine in-licensing opportunities and developing and launching Pfizer’s first clinical cancer vaccine program, which deployed a variety of vaccine platforms and immune modulators to create a multi-component vaccine-based immunotherapy regimen. Prior to joining Pfizer, Dr. Jooss served as vice president of research at Cell Genesys, where she oversaw all research activities related to the company’s cancer vaccine and oncolytic virotherapy programs. She is on the editorial board of Molecular Therapy and the Journal of Gene Medicine and is a member of the Immunology and Educational Committee of the American Society of Gene & Cell Therapy (ASGCT) and the Industry Task Force of the Society for Immunotherapy of Cancer (SITC). Dr. Jooss received a Ph.D. in molecular biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania.

Patrick Ott, M.D., Dana-Farber Cancer Institute

Laszlo Radvanyi Ph.D., Senior Vice President, Senior Scientific Advisor, Immunology, Immuno-Oncology, EMD Serono

Laszlo Radvanyi earned his Ph.D. degree in Clinical Biochemistry in 1996 at the University of Toronto, Toronto, Canada performing his thesis work on T-cell immunology. Dr. Radvanyi (Laszlo) joined EMD Serono (Merck KGaA, Darmstadt, Germany) in autumn 2015 as Senior Vice President (SVP), Global Head of the Immuno-Oncology Translational Innovation Platform (TIP) where he oversaw the day-to-day research operations in immuno-oncology at the company for 1.5 years. Laszlo’s key role coming into this position was to perform a much-needed rebuilding and re-organization of the Immuno-Oncology TIP as well as re-focusing and pruning the pipeline. He doubled the size of the TIP within this time period hiring key talent and restructured the organization establishing key human tumor immunology research areas and addressing key gaps in the pipeline in immune costimulation and the targeting of new tumor immune suppressive pathways. Laszlo also spearheaded a number of new company partnerships in key immuno-oncology areas, such as a deal with Domain Therapeutics (Strasbourg, France) in the adenosine receptor antagonist space, and a large deal with F-Star (Cambridge, UK) bringing in a new bispecific IND-enabled molecule targeting PD-L1 and Lag3. He also established academic alliances in the biomarker space, such as a comprehensive alliance with MD Anderson Cancer Center focusing on biomarker-driven clinical trials on key EMD Serono immuno-oncology pipeline assets. In May 2017, Laszlo transitioned to a more strategic role at EMD Serono as the Global Senior Scientific Advisor in Immuno-Oncology and Immunology where he plays a central scientific advisory role for all immuno-oncology and immunology programs, develops major academic center alliances, participates in a team developing new combination immunotherapy opportunities with avelumab (anti-PD-L1) as part of EMD Serono’s alliance with Pfizer in this area, and works on core team developing key scientific leadership strategies within EMD Serono/Merck KGaA. Prior to joining EMD Serono, Laszlo was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Center in Houston for about 10 years. While at M.D. Anderson, he established a GMP-grade T-cell therapy manufacturing program for metastatic melanoma using expanded tumor-infiltrating lymphocytes (TIL) and performed basic research on TIL biology and effector function focusing on TNF-R family costimulation and CD8+ T-cell differentiation where he made new discoveries on the role of BTLA in T cells. Laszlo was co-PI or co-investigator on a number of TIL clinical trials testing new methods to augment TIL adoptive transfer therapeutic efficacy in metastatic melanoma, including development of retroviral gene T-cell transduction approaches. In addition to his work on TIL therapy and basic research, Laszlo was tasked to establish a new Immunomonitoring Core Facility as part of MD Anderson’s Cancer Center Support Grant infrastructure. He established and directed this facility for 8 years (2005-2013) hiring all the staff and running the day-to-day activities of the facility.Between joining EMD Serono and leaving MD Anderson Cancer Center in 2014, Laszlo decided to diversity his activities into the biotechnology sector and helped start a biotechnology company to commercialize TIL therapy for melanoma and other cancers. He was the founding CSO for Lion Biotechnologies (recently renamed Iovance Therapeutics) for 1.5 years and designed and built the biotech’s 8,000 sq. ft. R&D facility at the University of South Florida’s Innovation Center in Tampa, FL. Laszlo oversaw the hiring of the research staff and lead research and development activities leading to two IND submissions in collaboration with Moffitt Cancer Center. Laszlo has authored over 110 papers, has served on the advisory board of a number of pharma and biotech companies, reviewed for numerous journals in the tumor immunology space, and has sat on a number of national and international research grant review panels, including the NIH-NCI, NHLBI, CIHR, BioCanRx, and EU Framework Program (FP). He is on the Keystone Conferences Scientific Advisory Board, is on editorial board of the Journal of Immunotherapy for Cancer (JITC), and sits on the Industry Advisory Council of the Society for Immunotherapy of Cancer (SITC).

Danny Wells, Ph.D., Scientist, Informatics, Parker Institute for Cancer Immunotherapy

Danny Wells is a biologist and data scientist at the Parker Institute for Cancer Immunotherapy where he leads sequencing informatics and immunogenomics efforts, including co-leading the TESLA project. Prior to joing the Parker Institute he completed a postdoctoral fellowship in evolutionary developmental biology at UC-Berekeley and a Ph.D. in applied math at Northwestern, where his research focused broadly on in silico models of tumor-immune interactions and machine learning.

Theresa Zhang, Ph.D., Vice President, Personalized Cancer Vaccines, Genocea

Theresa is the Vice President of Genocea. Before that, Dr. Zhang joined PGDx from Merck Research Laboratories, where she held positions of increasing responsibility for identification and clinical implementation of predictive biomarkers for oncology compounds for over a decade. During her tenure at Merck, Dr. Zhang oversaw the development of specially designed CLIA assays for use in cancer clinical trials and advanced a number of candidate biomarkers for clinical validation. She also managed multiple external collaborations. Dr. Zhang received a Ph.D. from the University of Virginia and completed a Postdoctoral Fellowship in bioinformatics at Cold Spring Harbor Laboratories. Dr. Zhang is a co-author of numerous scientific publications and a frequent presenter at scientific meetings.

Targeting the Tumor Microenvironment

Stephen Cary, Ph.D., Co-Founder & CEO, Omniox

Stephen Cary is the co-founder and CEO of Omniox, and co-inventor of the H-NOX technology. Stephen identified H-NOX as a potential therapeutic platform while working at the University of California, Berkeley. He secured the first financial support for Omniox by winning the inaugural Rogers Family Foundation "Bridging the Gap" Award at QB3. Subsequently, Stephen and his team obtained multiple NIH SBIR awards and a Wellcome Trust Translation Award to build Omniox' operations and enable development of the H-NOX platform.

Prior to launching Omniox, Stephen worked at Genentech in Market Strategy, and before that in Immunology Research. He participated extensively in early stage development projects, concentrating on strategic processes of transitioning therapeutic candidates from late-stage research to early development, and provided market and endpoint inputs into design of clinical trials. Stephen obtained his PhD in Biological Chemistry with Michael Marletta at the University of Michigan, and his Bachelor of Science degree in Molecular Biophysics & Biochemistry at Yale University.

Zhao Chen, Ph.D., Investigator III, Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research

No biography available

Alan L. Epstein, M.D., Ph.D., Professor, Pathology, Keck School of Medicine, University of Southern California

Alan L. Epstein MD, PhD is a Professor at the Keck School of Medicine at the University of Southern California and has over 30 years of experience in the laboratory developing monoclonal antibodies and other reagents for the treatment of cancer. He has published over 150 papers in the field and has filed 25 patents including those describing the use of TNT antibodies for the imaging and therapy of cancer. Along with TNT antibodies, Dr. Epstein has invented the Lym-1 antibody for the treatment of lymphoma, vasopermeability enhancing antibodies to increase the uptake of drugs and antibodies in tumors, the LN panel of diagnostic antibodies, and most recently several novel fusion proteins for the immunotherapy of cancer. He has been a consultant for numerous biotechnology companies and is an accomplished speaker and scientist in his field. Dr. Epstein holds a bachelor’s degree in biology from Wesleyan University, Middletown, CT and obtained the MD and PhD degrees from the Medical Scientist Training Program at Stanford University School of Medicine. Before coming to the University of Southern California, Dr. Epstein started his academic career in the Department of Medicine, Division of Medical Oncology at the Northwestern University School of Medicine in Chicago.

Elizabeth Evans, Ph.D., Vice President, Preclinical Research, Vaccinex

Dr. Elizabeth Evans is currently Vice President of Preclinical Research at Vaccinex, with an M.S. degree in Microbiology and Immunology, and a PhD in Pathology from the University of Rochester, NY. She leads a team who discovered a novel mechanism of action for SEMA4D in tumor immunology (Evans EE et al. Cancer Immunol Res. 2015;3(6):689-701). Dr. Evans is primarily engaged in the discovery and pre-clinical testing of therapeutic antibodies and biological drug candidates to treat diseases, with a primary focus in oncology and neurodegenerative and autoimmune diseases. During her employment, Vaccinex has grown from a small and innovative start-up biotechnology team into a successful research and clinical development company, currently planning four clinical trials evaluating the clinical activity of humanized anti-semaphorin 4D antibody VX15/2503 in patients with advanced solid tumors, as well as an ongoing phase 2 clinical study enrolling late prodromal and early manifest patients with Huntington’s disease.

Dean W. Felsher, M.D., Ph.D., Director, Translational Research and Applied Medicine, Oncology Research, Stanford University School of Medicine

My laboratory studies how oncogenes initiate and maintain cancer. Our work has shown that the inactivation of oncogenes can be used to treat cancer.

My area of clinical expertise is in the treament of patients with cancer. I specialize in the treatment of patients with lymphoma.

Shawn Jensen, Ph.D., Senior Scientist, Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Portland Providence Medical Center

Dr. Jensen has spent more than 20 years studying the complex interactions of the immune system in the tumor microenvironment. His background in translational cancer immunotherapy developed during his graduate studies in the lab of Dr. Bernard A Fox at Oregon Health and Science University. His work described the impact of T cell polarization on successful cancer immunotherapy and was summarized in multiple manuscripts and a book chapter. Building on this work Dr. Jensen examined the impact of regulatory T cells on adoptive transfer and tumor regression and established collaborations in both the United States and Europe during these studies. These successful interactions led to multiple publications as well as opportunities for Dr. Jensen to present these findings at various scientific conferences including the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC).

Currently, Dr. Jensen is a Senior Scientist at the Robert W. Franz Cancer Research Center at the Earle A. Chiles Research Institute, a component of Providence Health and Services, where he embraces the vision of preclinical work leading to the next generation of clinical trials. He has focused his research on studying the presence of various immune cell subsets within the tumor microenvironment when different immunotherapy strategies are employed and has played a role in the clinical application of vaccine strategies for patients with cancer. Dr. Jensen has been funded by the National Cancer Institute, National Institutes of Health, and is currently the Principal Investigator on two collaborative research agreements with industry partners. He has active collaborations with academic investigators in the US and Europe, which cover both preclinical models and the evaluation of anti-cancer immunity in patients with cancer. As part of the team at the Earle A. Chiles Research Institute and the Providence Cancer Center, Dr. Jensen is playing an active role in the development of the next generation clinical trials for patients with cancers of the breast, colon, lung, prostate, melanoma, and head and neck cancer.

Sanjay Khare, Ph.D., President, ImmunGene

Dr. Khare founded ImmunGene in 2008, where he has been serving as a President and CEO. Previously, Dr. Khare spent almost 9 years at Amgen Inc with increasing responsibility to Scientific Director in the department of Inflammation/Immunology. While at Amgen, Dr. Khare co-discovered key immune co-stimulatory molecules such as B7RP1 and B cell activating Factor (e.g. BAFF). Dr. Khare led several drug discovery programs related to immune cell costimulation and bifunctional molecules to optimize therapeutics. Dr. Khare is co-inventor of several patents while working in Amgen and as an advisor to the start up Biotech companies. Several of these inventions have resulted in more than US$1B potential deals from large Pharmaceutical companies. Dr. Khare coauthored more than 50 scientific papers, abstracts and edited a book on TNF superfamily. Dr. Khare has successfully capitalized ImmunGene from Angel investors, VC fundings, non-profit organization (LLS) and the NIH-SBIR. Sanjay received his Ph.D. in Immunology at the All-India Institute of Medical Sciences, New Delhi, India and did his postdoctoral fellowship in the Immunology department at the Mayo Clinic and Medical School. He is a recipient of ASHI scholar award in 1997.

Suresh Kumar, Ph.D., Senior Director, R&D, Progenra, Inc.

Dr. Suresh Kumar is a cell biologist and biochemist with several years of specific expertise in ubiquitin research. He was a postdoctoral researcher in the laboratory of Dr. Serge Fuchs, a pioneer ubiquitin scientist at the University of Pennsylvania, where he studied the role of ubiquitin in regulating key cytokine receptors. He discovered that the E3 ubiquitin ligase SCFβ-TrCP degrades the IFNalpha receptor, reducing the efficacy of IFNalpha in treating malignant melanoma. Dr. Kumar was also instrumental in establishing the roles of kinases in ubiquitin pathway mechanisms. In addition, he has contributed to the fields of immunology and antiviral therapeutics. In his current role as Senior Director of R&D at Progenra, Dr. Kumar has responsibilities in lead discovery and lead optimization. A major focus of Dr. Kumar is the development of small molecule immune-oncology drugs targeting the ubiquitin pathway enzymes.

Osama Rahma, M.D., Assistant Professor, Medicine, Center for Immuno-Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School

During my training as a research fellow at the Vaccine Branch, National Cancer Institute, I was able to establish a strong background in immunotherapy. The Vaccine Branch investigated variety of novel cancer vaccines and studied factors that could inhibit the immune response triggered by vaccine therapy, such as immune checkpoints. Having the opportunity to be part of these breakthrough discoveries was very rewarding and taking these discoveries to the clinic was even more rewarding. During my clinical oncology fellowship training at NCI I developed a great interest in gastrointestinal (GI) malignancies, focusing mainly on pancreatic cancer. My research efforts had led to the development of few clinical protocols using immunotherapy in pancreatic cancer that are currently open for enrollment at NCI and elsewhere. As the hepatobiliary and pancreatic cancer team co-leader at University of Virginia I had the opportunity to be the Principal Investigator of three pharma-sponsored multi-center clinical trials, two of which investigated the effects of three different cancer vaccines in pancreatic cancer. I am also the chair of tow investigator-initiated clinical trials using an immune checkpoint inhibitor (anti-PD-1) in combination with neoadjuvant chemoradiation therapy in pancreatic and rectal cancer. I recently joined the Center for Immuno-Oncology at Dana-Farber Cancer Institute to be part of national and international efforts to advance the field of cancer immunotherapy. In this exciting era of cancer immunotherapy we are currently investigating the combinations of variety of novel immunotherapeutic agents in multiple tumor types and working on identifying biomarkers that could determine clinical response.

Svetlana Sadekova, Ph.D., Senior Principal Scientist, Head of Translational Pathology Group, Merck

Dr. Svetlana Sadekova is the Head of Experimental & Translational pathology at Merck S&D, Palo Alto, USA. She holds a Ph.D. in biochemistry and completed her post-doctoral studies in cellular and molecular biology at McGill University, Montreal, Canada which led to her appointment as Director of the Breast Cancer Functional Genomics group and as an Assistant Professor in the department of Oncology, McGill. In 2006, Dr. Sadekova joined the research team at Schering Plough developing cancer therapeutics and after an acquisition by Merck in 2010, she has focused on identifying and advancing lead biologics into clinical trials, and developing biomarker-based strategies for immuno-oncology programs. Her areas of expertise include oncology translational research, development of strategic partnerships for focused mechanism of action studies on immune-oncology drugs and biomarker development.

Michael R. Shurin, M.D., Ph.D., Professor, Pathology, Immunology, University of Pittsburgh Medical Center

After graduation from Moscow State Medical School in 1984, postgraduation training in clinical biochemistry and clinical immunology and obtaining his PhD degree in Immunopharmacology in 1991, Dr. Shurin joined the faculty of the Department of Pathology at the University of Pittsburgh Medical Center in 1991 where he is a Professor of Pathology and Immunology and a Director of the Division of Clinical Immunopathology. His main research interests are in the field of the tumor microenvironment, cancer-mediated immunomodulation and dendritic cell vaccines for cancer immunotherapy. Professor Shurin’s pioneering studies on the immunobiology of dendritic cells in cancer opened opportunities for developing novel therapeutic approaches that are based on the protection of dendritic cell vaccines from tumor-mediated immunosuppression and polarization. At present, Shurin’s research program focuses on the immune modulating properties of chemotherapy and modulation of the tumor microenvironmental elements, including dendritic cells, regulatory T cells, myeloid-derived suppressor cells and endothelial cells, as well as intratumoral cytokine network. Using a combination of immunological, molecular and gene therapeutic methodologies, Dr. Shurin’s team developed innovative immunotherapeutic, chemoimmunotherapeutic and nanotherapeutic approaches for cancer, which were successfully tested in the pre-clinical settings and are under investigation in clinical trials. Professor Shurin is an author of more than hundred peer-reviewed publications and numerous reviews, an editor of several books, including “Dendritic Cell in Cancer”, “Infection and Cancer” and “The tumor immunoenvironment” books, an organizer of several popular international conferences on Immune-Mediated Diseases, Immunodiagnostics and Immunomonitoring and Cancer Immunotherapy. He is a member of several grant review and editorial boards and many clinical and research societies.

David Wustrow, Vice President, Drug Discovery, FLX Bio, Inc.

David joined FLX in 2016 from Cleave Biosciences where he served as Vice President, Chemical and Pharmaceutical Sciences. At Cleave he led chemistry efforts directed towards the discovery and development of first-in-class drug products for solid and hematologic malignancies. Prior to this, he was Vice President, Medicinal Chemistry and Executive Director of Scientific Assessment and Licensing at XenoPort, Executive Director of Chemistry at Neurogen, and Senior Director of Neuroscience Chemistry at Pfizer, where he led cross-functional teams to deliver preclinical development candidates for the treatment of pain, inflammation and psychiatric disorders.

David received his B.S. degree from Pennsylvania State University and holds a Ph.D. in Organic Synthesis from The University of Rochester. He is the author of over 40 peer-previewed publications and an inventor on over 30 U.S. patents.